✨ Your Portfolio is fetched and updated from zerodha.
Micro Miscellaneous

Remus Pharmaceuticals Ltd.

REMUS

Market Cap
₹1,080 Cr.
P/E
50.13

Remus Pharmaceuticals Ltd.

  • Remus Pharmaceutical
  • The Yamuna Syndicate
  • Uniphos Enterprises
FAQs on Remus Pharmaceuticals Ltd. Shareprice

Remus Pharmaceutical has given better returns compared to its competitors.
Remus Pharmaceutical has grown at ~1.75% over the last 1yrs while peers have grown at a median rate of 1.67%

There is insufficient historical data to gauge this.
Latest PE of Remus Pharmaceutical is 50.13

View FAQ's On Business
Growth Table
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Balance Sheet
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Cash Flow
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Quarterly Results
  • Remus Pharmaceuticals Ltd.
  • The Yamuna Syndicate
  • Uniphos Enterprises
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Remus Pharmaceuticals Ltd. Financials

Balance sheet of Remus Pharmaceutical is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Remus Pharmaceutical is increasing.
Latest net debt of Remus Pharmaceutical is -₹25.15 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹42.07 Crs.

Yes, profit is increasing.
The profit of Remus Pharmaceutical is ₹21.54 Crs for Mar 2024, ₹8.5 Crs for Mar 2023 and ₹3.43 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Remus Pharmaceutical latest dividend payout ratio is 4.1% and 3yr average dividend payout ratio is 3.33%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech